FibroGen Management
Management criteria checks 2/4
FibroGen's CEO is Thane Wettig, appointed in Jul 2023, has a tenure of less than a year. total yearly compensation is $3.64M, comprised of 15.7% salary and 84.3% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $177.58K. The average tenure of the management team and the board of directors is 2.8 years and 5.4 years respectively.
Key information
Thane Wettig
Chief executive officer
US$3.6m
Total compensation
| CEO salary percentage | 15.7% |
| CEO tenure | less than a year |
| CEO ownership | 0.2% |
| Management average tenure | 2.8yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Mar 22
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise
Feb 05FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%
Dec 22A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)
Nov 24Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)
Apr 18Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?
Feb 13The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts
Nov 12Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?
Oct 09FibroGen completes patient enrollment for Roxadustat to treat anemia in patients
Aug 26FibroGen Q2 2022 Earnings Preview
Aug 05Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?
Jul 06Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?
Mar 31Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook
Mar 05Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?
Dec 08News Flash: 10 Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Earnings Are Under Threat
Aug 12Downgrade: Here's How Analysts See FibroGen, Inc. (NASDAQ:FGEN) Performing In The Near Term
Jul 17Is FibroGen A Buy Going Into Roxa AdCom?
Jul 13FibroGen in pact for three HiFiBiO programs in cancer and autoimmune disease
Jun 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$4m | US$573k | -US$284m |
| Sep 30 2023 | n/a | n/a | -US$294m |
| Jun 30 2023 | n/a | n/a | -US$322m |
| Mar 31 2023 | n/a | n/a | -US$307m |
| Dec 31 2022 | US$3m | US$535k | -US$294m |
| Sep 30 2022 | n/a | n/a | -US$362m |
| Jun 30 2022 | n/a | n/a | -US$220m |
| Mar 31 2022 | n/a | n/a | -US$281m |
| Dec 31 2021 | US$3m | US$510k | -US$290m |
| Sep 30 2021 | n/a | n/a | -US$215m |
| Jun 30 2021 | n/a | n/a | -US$231m |
| Mar 31 2021 | n/a | n/a | -US$183m |
| Dec 31 2020 | US$4m | US$263k | -US$189m |
Compensation vs Market: Thane's total compensation ($USD3.64M) is above average for companies of similar size in the US market ($USD674.55K).
Compensation vs Earnings: Thane's compensation has increased whilst the company is unprofitable.
CEO
Thane Wettig (58 yo)
less than a year
Tenure
US$3,640,829
Compensation
Mr. Thane Wettig serves as Director of FibroGen, Inc. since October 2, 2023. He serves as Chief Executive Officer at FibroGen, Inc. since October 2, 2023 and served as Interim Chief Executive Officer since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$3.64m | 0.16% $ 177.6k | |
| Senior VP & CFO | 2.7yrs | US$3.09m | 0.049% $ 54.6k | |
| Senior Vice President of China Operations | 17.3yrs | US$3.11m | 0.21% $ 232.1k | |
| Founder | 29.3yrs | no data | no data | |
| Chief Scientific Officer | 2.8yrs | no data | no data | |
| Vice President of Corporate FP&A and Investor Relations | no data | no data | no data | |
| Chief Legal Officer | 8.1yrs | no data | no data | |
| Chief People Officer | 3yrs | no data | no data | |
| Chief Business Officer | 3.5yrs | no data | no data | |
| Senior Vice President of Pharmaceutical Development | 2.3yrs | no data | no data | |
| Senior VP of Regulatory | less than a year | no data | no data | |
| Senior VP & Chief Medical Officer | less than a year | no data | no data |
2.8yrs
Average Tenure
55yo
Average Age
Experienced Management: FGEN's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$3.64m | 0.16% $ 177.6k | |
| Independent Director | 8.8yrs | US$370.53k | 0.021% $ 23.3k | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.9yrs | US$388.03k | 0.021% $ 24.1k | |
| Independent Director | 8.6yrs | US$385.53k | 0.026% $ 29.0k | |
| Independent Chairman of the Board | 14.1yrs | US$499.58k | 0.082% $ 92.1k | |
| Independent Director | 6.7yrs | US$383.03k | 0.037% $ 41.9k | |
| Independent Director | 5.4yrs | US$375.53k | 0.023% $ 26.2k | |
| Independent Director | 3.8yrs | US$392.55k | 0.021% $ 23.1k | |
| Independent Director | 3.8yrs | US$373.03k | 0.020% $ 22.2k |
5.4yrs
Average Tenure
62yo
Average Age
Experienced Board: FGEN's board of directors are considered experienced (5.4 years average tenure).